The CLDN18.2-targeting asset is currently under priority review by China’s NMPA, which could see it join the country’s ...

The 69-year-old was left with chronic pain after spending a lifetime on her feet helping patients. Then a conversation with a ...

Several popular breakfast foods are rich in a vitamin that may prevent cancer, but what if you already have it? Here's what ...

June 5 (Reuters) - Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche, showed encouraging tolerability in a mid-stage trial, bolstering its push to take ...

VRB-103, a once-weekly oral amylin analog, demonstrated high potency and strong selectivity in vitro for human amylin receptors VRB-103 expected to enter the clinic in H2 2026 as a monotherapy ...